Browse Category

NASDAQ:BDRX News 10 December 2025

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options. StockInvest+2MarketWatch+2 This article looks at where BDRX stock stands on December 10, 2025, the latest clinical and regulatory news from Biodexa, the company’s increasingly complex capital structure, and how third‑party models and analysts are framing the risk–reward profile into 2026.
Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

Published: December 10, 2025 — U.S. pre‑market sessionAll data and news current as of early U.S. trading hours on Dec. 10, 2025. Fed Day Starts Quiet for Indexes, Wild for Individual Stocks Wall Street is waking up to a classic “calm on the surface, chaos underneath” kind of Fed day. S&P 500, Nasdaq 100, Dow Jones and Russell 2000 futures are only fractionally lower or higher in pre‑market trading, with moves generally within a few tenths of a percent as investors wait for the Federal Reserve’s final rate decision of 2025.Yahoo Finance+3StockAnalysis+3Morningstar+3 Markets widely expect another 25‑basis‑point cut, but the
Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy

Top Pre‑Market Gainers Today, December 10, 2025: ASPC, ENVB, BDRX and APVO Lead Fed‑Day Frenzy

U.S. stock futures are edging higher early Wednesday as traders brace for the Federal Reserve’s final policy decision of 2025, with markets pricing in a high probability of another 25‑basis‑point rate cut. Futures on the Nasdaq 100, S&P 500 and Dow are modestly green, while the 10‑year U.S. Treasury yield hovers near 4.18% and commodities like silver trade at record highs above $61 an ounce. TipRanks+1 Beneath the calm surface of the indexes, however, the real fireworks are in pre‑market trading. A handful of thinly traded SPACs and micro‑cap biotechs are posting triple‑digit gains, joined by a distressed hotel REIT

Stock Market Today

SAP stock price: Treasury stake tops 5% as buyback focus builds into next week

SAP stock price: Treasury stake tops 5% as buyback focus builds into next week

7 February 2026
SAP SE closed at 171.22 euros on Xetra Friday, up 0.43%, after disclosing its treasury shares rose above 5% of capital, reaching 61,737,035 shares. The increase follows the launch of a buyback plan worth up to 2.6 billion euros through July 2026. SAP’s U.S. shares finished at $203.34. Investors await SAP’s Integrated Report on Feb. 26 and next results on April 23.
L’Oreal share price slips into weekend as OR.PA heads for annual results test

L’Oreal share price slips into weekend as OR.PA heads for annual results test

7 February 2026
L’Oréal shares closed at 394.05 euros in Paris on Friday, down 0.16%, marking a second straight session of losses. The company will release its 2025 annual results after markets close on Feb. 12, with a financial meeting set for Feb. 13. About 319,000 shares traded Friday in a range between 385.70 and 395.10 euros. The STOXX 600 rose 0.9% to 617.12 points.
Go toTop